At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Efavaleukin alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian Subjects
In Brief
A Phase 1 clinical trial evaluating Efavaleukin alfa for Inflammatory Diseases. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Diseases
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedAug 3, 2021
Enrollment StartAug 9, 2021
Primary CompletionOct 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.9 years ago
Interventions
Efavaleukin alfadrug
Administered as a single dose SC injection.